The in vitro effect of new muramyl peptide derivatives on cytotoxic activity of NK (Natural Killer) cells from hamsters bearing Ab Bomirski melanoma

Biotherapy

Volumn 10, Issue 2, 1997, Pages 161-168

  Sosnowska, Danuta ^a,b   Mysliwski, Andrzej ^a   Dzierzbicka, Krystyna ^a   Kolodziejczyk, Aleksander M ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Hamster; Melanoma; Muramyl peptide; NK cells

Indexed keywords

MURAMYL DIPEPTIDE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD; CELL STRAIN K 562; CONTROLLED STUDY; CYTOTOXICITY; DRUG ISOLATION; EFFECTOR CELL; ERYTHROLEUKEMIA; HAMSTER; IN VITRO STUDY; MELANOMA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TARGET CELL;

EID: 0030803178     PISSN: 0921299X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02678543     Document Type: Article

References (30)

1. Adam A, and Lederer E. Muramylpeptides äs immunomodulators. ISI Atlas Sei 1988; 1: 205-214.
2. Sone S. and Fidler U. Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages. J.Immunol. 1980; 125: 2454-2460.
3. Sone S, Lopez-Bernstein g, and Fidler U. Potentiation of antitumor cytotoxicity and production of tumor cytolytic factors in human
4. blood monocytes by human recombinant interferon-gamma and muramyl dipeptide derivatives. Cancer Immunol. Immunother 1986; 21: 93-99.
5. Sone S, Utsugi T, Tandon P, and Ogawara M. Potentiation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state. Cancer Immunol Immunother 1986; 22: 191-196.
6. Bigda J, Mysliwski A, Sosnowska D, Romanowski P, and Bomirski A. Natural killer sensitivity of tumor cells isolated from primary and metastatic lesions of four Bomirski melanoma variants. Clin Exp Metastasis 1990; 9: 57-65.
7. Bigda J, Mysliwski A, Mysliwska J, Witkowski J, Kmiec Z, and Bomirski A. Natural killer sensitivity of four Bomirski melanoma variants. Cancer Lett 1989; 44: 67-72.
8. O' Reilly T, and Zak O. Enhancement of the effectiveness of antimicrobial therapy by muramyl peptide immunomodulators. Clin Infect Dis 1989; 14: 1100-1109.
9. Osada Y, Mitsuyama M, Une T, Matsumoto K, Otani T, Satoh M, Ogawa H, and Nomoto K. Effect of L l S-MDP(Ala), a synthetic derivative of muramyl dipeptide, on nonspecific resistance of mice to microbial infections. Infect Immun 1982; 37: 292-300.
10. Bomirski A, Slominski A, and Bigda J. The natural history of a family of transplantable melanomas on hamsters. Cancer Met. Rev. 1988; 7: 95-118.
11. Sosnowska D. and Mysliwski A. Unpublished data.
12. Lemaire I, and St-Jean M. Modulation of lung - associated natural killer activity by resident and activated alveolar macrophage. Immunol Invest 1990; 19: 27-40.
13. Masihi KM, Lange W, and Rohde-Schultz B. Modulation of natural killer cytotoxicity by muramyl dipeptide and trehalose dimycolate incorporated in squalane droples. Cancer Immunol Immunother 1987; 24: 19-23.
14. Sharma SD, Tsai V, Krahenbuhl JL, and Remington JS. Augmentation of mouse natural killer cell activity by muramyl dipeptide and its analogs. Cell Immunol 1981; 62: 101-109.
15. Talmadge JE, Schneider M, Collins M, Phillips Herberman H, and Wiltrout RH. Augmentation of NK cell activity in tissue specific sites by liposomes incorporating MTP-PE. J Immunol 1985; 135: 1477-1483.
16. Roitt I, Brostoff J, and Male D. Immunology. Gower Medical Publishing 1989.
17. Sanceau J, Falcoff R, Beranger D, Carter DB, and Wietzerbin J. Secretion of interleukin-6 (IL-6) by human monocytes stimulated by muramyl dipeptide and tumor necrosis factor alfa. Immunology 1990; 69: 52-56.
18. Souvannavong V, and Adam A. Restoration and stimulation of in vitro immune response of B cells to sheep erythrocytes by interleukins and muramyl dipeptide (MDP). Bioche Biophys Res Commun 1984; 125: 431
19. Souvannavong V, and Adam A. N-acetylmura-myl-L-alanylD-isoglutamine stimulates the immune response of B cells. J Chromatogr 1988; 440: 95-103.
20. Souvannavong V, Brown S, and Adam A. The synthetic immunomodulator muramyl dipeptide (MDP) can stimulate activated B cell. Molec Immunol 1988; 25: 385-391.
21. Souvannavong V, and Adam A. Increased expression of alkaline phospatase activity in stimulated B lymphocytes by muramyl dipeptide. Immunol Lett 1990; 29: 247-252.
22. Dziarski R. Enhancement of B-cell stimulation by muramyl dipeptide through a mechanism not involving interleukin 1 or increased Ca2+ mobilization or protein kinase C activation. Cell Immunol 1988; 111: 10-27.
23. Sumaroka MV, Litvinov IS, Khaidukov SV, Golovina TN, Kamraz MV, Komaleva RL, Andronowa TM, Makarov EA, Nesmeyanov VA and Ivanov VT. Muramyl peptide-bindind sites are located inside target cells. FEBS Lett 1991; 295: 48-50.
24. Lasek W, and Skorski T. Naturalne komorki cytotoksyczne typu NK. Ultrastruktura i funkcja komorki 1991; .5: 80-116.
25. Adam A, Petit J-F, Lefrancier P, and E Lederer. Muramyl peptides. Molec Cell Biocheml981; 41: 27-47.
26. Kolodziejczyk AM, and Kolodziejczyk A.S. Muramylopeptydy i ich wlasciwosci farmakologiczne. Post Biochem 1987; 33: 203-229.
27. Kotani S, Tsujimoto M, Koga T, Nagao S, Tanaka A, and Kawata S. Chemical structure and biological activity relationship of bacterial cell walls and muramyl peptides. Fed Proc 1986; 45: 2534-2540.
28. Le Garrec Y, and Mortin A. Modulation of natural killer by muramyl peptides: relationship with adjuvant and antiinfectious properties. Nat Immun Cell Growth Regul 1987; 6:65-76.
29. Romanowski P, Dzierzbicka K, Mysliwski A, and Kolodziejczyk AM. Syntetyczne immunomodulatory wzorowane na naturalnych produktach mikroorganizmow. Post Bioch 1991 ; 37: 159-171.
30. Sosnowska D, Dzierzbicka K, Mysliwski A, and Kolodziejczyk AM. Investigation of stimulating effect of MDP derivatives on the cytotoxic activity of human blood in vitro. 3rd International Symposium on Molecular Aspects of Chemotherapy 19-21 June, Abstracts, p.57; 1991.